Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases
Breast Cancer · 2024
DOI: 10.1007/s12282-024-01565-7 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Breast Cancer, 2024. Verfasst von Alexandre De Moura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France. alexandre.demoura@curie.fr. Hauptthemen laut MEDLINE: Brain Neoplasms, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms, Camptothecin. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results.
Methods
We set up an ambispective bicentric cohort study to assess the real-world effectiveness and safety of SG in patients with mTNBC treated at Institut Curie Hospitals, with a focus on patients with brain metastases.
Results
This study included 99 patients treated through the French Early Access Program to SG from May 2021 to January 2023. Median age was 55 years [26–89], N = 8 patients (8%) had BRCA1/2 mutation, N = 12 (12%) de novo stage IV disease and N = 31 (31%) brain metastases. Patients had previously received a median of two [1–10] lines of treatment in advanced setting. After a median follow-up of 9.7 months, the median progression-free survival (PFS) and overall survival (OS) were 3.9 months (95%CI[3.4–5.0]) and 8.6 months (95%CI[7.1–11.9]), respectively, while objective response rate was 29% (95%CI[21–39]). Among patients with brain metastases, median PFS and OS were 3.7 months (95%CI[2.6–6.2]) and 6.7 months (95%CI[6.3–NR]), respectively, with intracranial tumor responses. Dose reductions were required in N = 17 patients (17%) within a median of three [2–11] cycles, due to gastrointestinal toxicity ( N = 6; 6%), hematological toxicity ( N = 9; 9%) including febrile neutropenia ( N = 2; 2%), liver enzyme elevation ( N = 1; 1%), and physical deterioration ( N = 1; 1%). There was no related death to SG.
Conclusions
The observed response rate and safety of SG are consistent with the results of the ASCENT trial, with efficacy observed in patients with brain metastases, but observed PFS and OS are numerically shorter.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France. alexandre.demoura@curie.fr.
- Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.
- Department of Pharmacy, Institut Curie, Paris & Saint-Cloud, France.
- UVSQ, Université Paris-Saclay, Saint-Cloud, France.
- Université Paris Cité, Paris, France.
- Université Paris Cité, CiTCoM, CNRS UMR 8038, Inserm U1268, Paris, France.
Zitieren
APA
De Moura, A., Loirat, D., Vaillant, S., Korbi, S., Kiavue, N., Bello Roufai, D., Escalup, L., Desmaris, R., Vaflard, P., Cottu, P., Pierga, J. Y., Bidard, F. C., Cabel, L., & Acramel, A. (2024). Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. https://doi.org/10.1007/s12282-024-01565-7
Vancouver
De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 2024. doi:10.1007/s12282-024-01565-7
BibTeX
@article{DeMoura2024,
author = {De Moura, Alexandre and Loirat, Delphine and Vaillant, Sarah and Korbi, Sinen and Kiavue, Nicolas and Bello Roufai, Diana and Escalup, Laurence and Desmaris, Romain and Vaflard, Pauline and Cottu, Paul and Pierga, Jean-Yves and Bidard, François-Clément and Cabel, Luc and Acramel, Alexandre},
title = {Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases},
journal = {Breast Cancer},
year = {2024},
doi = {10.1007/s12282-024-01565-7}
}
EUVIMED